News
  • Andrea
    author-profile

    Andrea right arrow

    Author

    • 2 minutes read

    Coinbase CEO Brian Armstrong Bags $130M for Longevity Startup NewLimit

    Story Highlights
    • Coinbase CEO Brian Armstrong’s biotech startup NewLimit raised $130M to fight aging through cell reprogramming.

    • The Series B round values NewLimit at $810M, with backing from top investors like Kleiner Perkins and Founders Fund.

    • Armstrong is also pushing U.S. lawmakers to pass stablecoin legislation.

    While most crypto CEOs are busy navigating market volatility,Brian Armstrong is playing a far bigger game – taking on human aging and Washington regulations at the same time. Not exactly your typical founder story, right? 

    One moment he’s rallying for stablecoin legislation on Capitol Hill, the next he’s funding research to literally reverse the aging process.

    Here’s the latest on Armstrong, for all Coinbase enthusiasts out there! 

    NewLimit Raises $130M to Rewire Human Longevity

    Armstrong’s biotech venture NewLimit, co-founded with former GV partner Blake Byers and stem cell scientist Jacob Kimmel, just closed a $130 million Series B round. The startup, now valued at $810 million, is developing therapies that aim to restore youthful function to aging cells through epigenetic reprogramming.

    Early results are promising. The team has identified three prototype medicines targeting liver cells – improving their fat and alcohol processing capabilities in lab tests. 

    While human trials are still years away, NewLimit is expanding into immune system research, with Armstrong citing the urgency of fighting what he calls the “largest source of human tragedy” – aging.

    The round was led by Kleiner Perkins and backed by a powerful lineup of investors including Founders Fund, Elad Gil, Patrick Collison, and Garry Tan.

    Say No to Aging: Tech Titans Are All In!

    Armstrong isn’t alone in this mission. He joins the ranks of tech elites like Jeff Bezos, Larry Ellison, and Vitalik Buterin – all pouring hundreds of millions into anti-aging research. But Armstrong’s approach is distinctive: part-scientist, part-operator, and always ten steps ahead.

    Fighting for Stablecoin Regulations

    The Coinbase CEO hasn’t loosened his grip on crypto advocacy. Just yesterday on X, he called on the U.S. Senate to move forward on the GENIUS Act – a stablecoin regulation bill that could finally bring clear rules to the space.

    The GENIUS Act would introduce a federal licensing regime, enforce reserve requirements for issuers, and create a dual regulatory model – splitting oversight between federal and state levels depending on issuer size. 

    The push comes just as the Treasury predicts stablecoins could surge from $230B to $2T by 2028, presenting both an opportunity and a risk to traditional banking systems.

    Never Miss a Beat in the Crypto World!

    Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

    Here’s how we see it: Brian Armstrong is betting on the future, and he’s doing it from all sides.

    FAQs

    What is Brian Armstrong’s biotech company NewLimit?

    NewLimit is a biotech startup co-founded by Brian Armstrong to reverse aging via epigenetic cell reprogramming.

    What does the GENIUS Act mean for stablecoin regulation?

    The GENIUS Act proposes federal and state oversight, reserve rules, and licenses to regulate stablecoin issuers.

    Show More

    Related Articles

    Back to top button